News Releases

Printer friendly version

Protox Strengthens Intellectual Property Portfolio with New Patent Application

Wednesday, June 14, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office entitled “Modified Protein Toxins and Use Thereof for Treating Disease”. The patent application provides added protection for drug candidates generated through the PORxin™ platform whose binding sites are altered to target certain types of cells including cancer cells.

“This application demonstrates our commitment to build a broad intellectual property portfolio around our PORxin™ platform,” said Dr. Fahar Merchant, President and CEO of the Company. “Altering the binding site enables us to increase the specificity of our drugs, which in turn allows us greater flexibility to administer and treat a much wider range of diseases. In addition, we believe these potential drug candidates will enhance our ability to establish drug development partnerships.”

About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company’s PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, pro-aerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox is in Phase I clinical trial with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.

For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com